ASSERTIO HOLDINGS INC (ASRT)
US04546C2052 - Common Stock
Overall ASRT gets a fundamental rating of 3 out of 10. We evaluated ASRT against 194 industry peers in the Pharmaceuticals industry. ASRT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASRT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ASRT has reported negative net income.
In the past year ASRT had a positive cash flow from operations.
In the past 5 years ASRT reported 4 times negative net income.
Of the past 5 years ASRT 4 years had a positive operating cash flow.
1.2 Ratios
ASRT has a better Return On Assets (-24.81%) than 60.94% of its industry peers.
ASRT's Return On Equity of -52.47% is in line compared to the rest of the industry. ASRT outperforms 56.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.81% | ||
| ROE | -52.47% | ||
| ROIC | N/A |
ROA(3y)-29.94%
ROA(5y)-28.06%
ROE(3y)-64.41%
ROE(5y)-123.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ASRT has declined.
ASRT's Gross Margin of 70.31% is fine compared to the rest of the industry. ASRT outperforms 75.00% of its industry peers.
In the last couple of years the Gross Margin of ASRT has declined.
ASRT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.31% |
OM growth 3YN/A
OM growth 5Y-12.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-2.65%
2. Health
2.1 Basic Checks
ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASRT has more shares outstanding
The number of shares outstanding for ASRT has been increased compared to 5 years ago.
Compared to 1 year ago, ASRT has an improved debt to assets ratio.
2.2 Solvency
ASRT has an Altman-Z score of -2.39. This is a bad value and indicates that ASRT is not financially healthy and even has some risk of bankruptcy.
ASRT has a Altman-Z score (-2.39) which is in line with its industry peers.
ASRT has a debt to FCF ratio of 1.91. This is a very positive value and a sign of high solvency as it would only need 1.91 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.91, ASRT belongs to the best of the industry, outperforming 94.79% of the companies in the same industry.
A Debt/Equity ratio of 0.30 indicates that ASRT is not too dependend on debt financing.
ASRT's Debt to Equity ratio of 0.30 is in line compared to the rest of the industry. ASRT outperforms 40.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.91 | ||
| Altman-Z | -2.39 |
ROIC/WACCN/A
WACC9.1%
2.3 Liquidity
A Current Ratio of 2.01 indicates that ASRT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.01, ASRT is doing worse than 63.54% of the companies in the same industry.
ASRT has a Quick Ratio of 1.57. This is a normal value and indicates that ASRT is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ASRT (1.57) is worse than 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.01 | ||
| Quick Ratio | 1.57 |
3. Growth
3.1 Past
ASRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -177.66%.
ASRT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.80%.
The Revenue for ASRT have been decreasing by -13.38% on average. This is quite bad
EPS 1Y (TTM)-177.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.48%
Revenue 1Y (TTM)-25.8%
Revenue growth 3Y12.68%
Revenue growth 5Y-13.38%
Sales Q2Q%-18.04%
3.2 Future
ASRT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.89% yearly.
Based on estimates for the next years, ASRT will show a decrease in Revenue. The Revenue will decrease by -3.19% on average per year.
EPS Next Y81.62%
EPS Next 2Y39.19%
EPS Next 3Y28.89%
EPS Next 5YN/A
Revenue Next Year-20.39%
Revenue Next 2Y-8.71%
Revenue Next 3Y-3.19%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ASRT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASRT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, ASRT is valued cheaply inside the industry as 97.40% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.81 | ||
| EV/EBITDA | -3.03 |
4.3 Compensation for Growth
ASRT's earnings are expected to grow with 28.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.19%
EPS Next 3Y28.89%
5. Dividend
5.1 Amount
No dividends for ASRT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASSERTIO HOLDINGS INC
NASDAQ:ASRT (11/15/2024, 8:00:00 PM)
After market: 0.8317 +0.02 (+2.5%)0.8114
-0.03 (-3.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap77.36M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.81% | ||
| ROE | -52.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.31% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.01 | ||
| Quick Ratio | 1.57 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-177.66%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y81.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-25.8%
Revenue growth 3Y12.68%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y